| Literature DB >> 29330659 |
Masato Kajikawa1, Tatsuya Maruhashi2, Takayuki Hidaka2, Yukiko Nakano2, Satoshi Kurisu2, Takeshi Matsumoto2, Yumiko Iwamoto2, Shinji Kishimoto2, Shogo Matsui2, Yoshiki Aibara3, Farina Mohamad Yusoff3, Yasuki Kihara2, Kazuaki Chayama4, Chikara Goto5, Kensuke Noma1,3, Ayumu Nakashima3, Takuya Watanabe6, Hiroshi Tone6, Masanobu Hibi6, Noriko Osaki6, Yoshihisa Katsuragi6, Yukihito Higashi7,8.
Abstract
PURPOSE: The purpose of this study was to evaluate acute effects of coffee with a high content of chlorogenic acids and different hydroxyhydroquinone contents on postprandial endothelial dysfunction.Entities:
Keywords: Atherosclerosis; Chlorogenic acids; Endothelial function; Hydroxyhydroquinone
Mesh:
Substances:
Year: 2018 PMID: 29330659 PMCID: PMC6499758 DOI: 10.1007/s00394-018-1611-7
Source DB: PubMed Journal: Eur J Nutr ISSN: 1436-6207 Impact factor: 5.614
Fig. 1Flow chart of study design
Composition of the intervention products
| Beverage A | Beverage B | Beverage C | |
|---|---|---|---|
| Drink volume, g/serving | 185 | 185 | 185 |
| Chlorogenic acids (9 analogues), mg/serving | 412 | 378 | 0 |
| Hydroxyhydroquinone, mg/serving | 0.11 | 0.76 | 0.10 |
| Caffeine, mg/serving | 69 | 75 | 59 |
| Energy, kcal/serving | 9 | 11 | 2 |
Chlorogenic acids (9 analogues) analogues present are the caffeoylquinic acids (3-CQA, 4-CQA, and 5-CQA), feruloylquinic acids (3-CQA, 4-CQA, and 5-CQA), and dicaffeoylquinic acids (3,4-di-CQA, 3,5-di-CQA, and 4,5-di-CQA)
Clinical characteristics of the subjects
| Variables | Study 1 ( | Study 2 ( |
|---|---|---|
| Age, year | 53 ± 19 | 56 ± 15 |
| Sex, men/women | 14/5 | 12/6 |
| Body mass index, kg/m2 | 24.5 ± 4.1 | 23.2 ± 3.1 |
| Systolic blood pressure, mmHg | 130 ± 11 | 128 ± 13 |
| Diastolic blood pressure, mmHg | 77 ± 9 | 81 ± 8 |
| Heart rate, bpm | 65 ± 8 | 63 ± 9 |
| HbA1c, % | 5.4 ± 0.3 | 5.5 ± 0.4 |
| Medical history, | ||
| Borderline hypertension | 6 (31.6) | 3 (16.7) |
| Stage 1 hypertension | 13 (68.4) | 15 (83.3) |
| Dyslipidemia | 9 (47.4) | 7 (38.9) |
| Diabetes mellitus | 0 (0) | 0 (0) |
| Previous coronary heart disease | 0 (0) | 0 (0) |
| Previous stroke | 0 (0) | 0 (0) |
| Current smoker | 0 (0) | 0 (0) |
| Medications, | ||
| Calcium-channel blockers | 7 (36.7) | 9 (50.0) |
| Renin angiotensin system inhibitors | 0 (0) | 0 (0) |
| Statins | 0 (0) | 0 (0) |
| Medically treated diabetes | ||
| Any | 0 (0) | 0 (0) |
| Insulin-dependent | 0 (0) | 0 (0) |
Results are presented as mean ± SD or number (%)
FMD values at baseline and during follow-up
| Study 1 | Study 2 | |||
|---|---|---|---|---|
| Beverage A | Beverage B | Beverage A | Beverage C | |
| Systolic blood pressure, mmHg | ||||
| Baseline | 130 ± 11 | 131 ± 11 | 128 ± 13 | 130 ± 14 |
| 1 h | 131 ± 13 | 128 ± 11 | 129 ± 12 | 132 ± 16 |
| 2 h | 130 ± 12 | 129 ± 13 | 128 ± 16 | 129 ± 16 |
| Chlorogenic acid, ng/mL | ||||
| Baseline | 0.7 ± 2.0 | 1.1 ± 3.0 | 1.1 ± 2.7 | 0.7 ± 2.8 |
| 1 h | 54.0 ± 20.5* | 56.5 ± 22.7* | 51.5 ± 22.5* | 0.3 ± 1.3† |
| 2 h | 50.3 ± 16.0* | 55.1 ± 23.3* | 56.7 ± 21.2* | 0.3 ± 1.2† |
| Triglycerides, mg/dL | ||||
| Baseline | 124 ± 63 | 117 ± 65 | 121 ± 67 | 111 ± 49 |
| 1 h | 159 ± 76* | 143 ± 72* | 140 ± 66* | 132 ± 48* |
| 2 h | 181 ± 90* | 188 ± 104* | 174 ± 74* | 167 ± 64* |
| Glucose, mg/dL | ||||
| Baseline | 95 ± 10 | 93 ± 6 | 92 ± 8 | 92 ± 7 |
| 1 h | 140 ± 32* | 139 ± 32* | 124 ± 23* | 130 ± 22* |
| 2 h | 120 ± 29* | 122 ± 24* | 112 ± 16* | 110 ± 18* |
| Insulin, µIU/L | ||||
| Baseline | 7 ± 5 | 6 ± 4 | 6 ± 4 | 6 ± 3 |
| 1 h | 55 ± 39* | 51 ± 36* | 42 ± 39* | 42 ± 27* |
| 2 h | 41 ± 28* | 45 ± 46* | 26 ± 22* | 27 ± 25* |
| 8-Isoprostane, pg/mL | ||||
| Baseline | 75 ± 48 | 55 ± 23 | 88 ± 67 | 73 ± 57 |
| 1 h | 56 ± 41 | 59 ± 46 | 75 ± 67* | 55 ± 23 |
| 2 h | 73 ± 60 | 69 ± 74 | 72 ± 59* | 64 ± 32 |
| High-sensitivity C-reactive protein, mg/dL | ||||
| Baseline | 0.10 ± 0.17 | 0.05 ± 0.04 | 0.07 ± 0.07 | 0.08 ± 0.17 |
| 1 h | 0.10 ± 0.17 | 0.05 ± 0.04 | 0.07 ± 0.07 | 0.09 ± 0.21 |
| 2 h | 0.10 ± 0.16 | 0.05 ± 0.04 | 0.07 ± 0.07 | 0.11 ± 0.25 |
| FMD, % | ||||
| Baseline | 4.5 ± 4.0 | 5.4 ± 4.8 | 3.1 ± 3.6 | 4.2 ± 3.6 |
| 1 h | 5.4 ± 4.5* | 4.9 ± 4.6 | 4.9 ± 2.1* | 4.1 ± 3.3 |
| 2 h | 6.0 ± 2.4* | 6.4 ± 4.4 | 4.6 ± 3.4* | 3.8 ± 3.7 |
*P < 0.05 vs. baseline
†P < 0.05 vs. Beverage A
Fig. 2Scatter plot shows the relationships between postprandial changes in FMD and postprandial changes in chlorogenic acid
Fig. 3Scatter plots show the relationships between postprandial changes in FMD (a 1 h after ingestion, b 2 h after ingestion) and 8-isoprostane at baseline